Finerenone Slows CKD Progression in Non-Diabetic Patients
A new clinical trial has shown that finerenone, a drug previously used to treat kidney damage in diabetic patients, may significantly slow the progression of chronic kidney disease (CKD) in non-diabetic individuals, according to a study published in the New England Journal of Medicine. The research involved 1,584 adults with CKD who did not have diabetes, revealing that the medication reduced kidney function decline and lowered cardiovascular risks.
What Happened
Researchers tested finerenone on 1,584 adults with reduced kidney function and high levels of protein in their urine, indicators of ongoing kidney damage. Half received the drug, while the other half received a placebo. Over three years, the group taking finerenone experienced a slower decline in kidney function compared to the placebo group. The drug also reduced the risk of severe complications by 23% and lowered cardiovascular hospitalizations and mortality. Proteinuria, a key marker of kidney damage, decreased by 41% on average in the treatment group, versus 9% in the placebo group.
Why It Matters
CKD affects approximately 800 million people globally, with more than half of cases occurring in individuals without diabetes. Historically, treatment options for non-diabetic CKD have been limited, leaving many patients without effective interventions. The study’s findings highlight a potential breakthrough for a population long underserved by medical advancements. By addressing both kidney and heart health, finerenone could transform care for millions facing progressive organ decline.
What May Happen Next
Regulatory agencies will need to evaluate the trial results before approving finerenone for non-diabetic CKD patients. If authorized, the drug could become a standard treatment, offering a dual benefit for kidney and cardiovascular health. However, further research may be required to confirm long-term safety and efficacy. Analysts suggest the findings could prompt updated guidelines for CKD management, though widespread adoption depends on cost, accessibility, and physician acceptance.
Frequently Asked Questions
What is chronic kidney disease? Chronic kidney disease is a progressive condition where kidney function declines over time, often without early symptoms. It can lead to kidney failure, heart disease, and other severe complications.
How does finerenone work? Finerenone targets mineralocorticoid receptors, reducing inflammation and fibrosis in the kidneys. It also lowers blood pressure and proteinuria, which are linked to kidney and heart damage.
Who was included in the study? The trial included 1,584 adults with non-diabetic chronic kidney disease, all showing reduced kidney function and elevated protein levels in their urine.
Could the approval of finerenone mark a turning point in treating non-diabetic kidney disease, or will additional hurdles delay its impact?